公开(公告)号：US20240000792A1

公开(公告)日：2024-01-04

申请号：US18463183

申请日：2023-09-07

Applicant: Calico Life Sciences LLC ,  AbbVie Inc.

Inventor： Kathleen Ann Martin ,  Carmela Sidrauski ,  Jennifer M. Frost ,  Yunsong Tong ,  Xiangdong Xu ,  SeungWon Chung ,  Qingwei Zhang ,  Lei Shi ,  Kathleen J. Murauski ,  Michael J. Dart ,  John T. Randolph

IPC: A61K31/538 ,  A61K31/343 ,  A61K31/353 ,  A61K31/357 ,  A61K31/36 ,  A61K31/404 ,  A61K31/4045 ,  A61K31/472 ,  A61K45/06 ,  C07C235/22 ,  C07D209/08 ,  C07D209/42 ,  C07D217/16 ,  C07D265/36 ,  C07D307/85 ,  C07D311/66 ,  C07D317/46 ,  C07D319/20 ,  C07D405/12 ,  C07D413/06 ,  C07D413/12 ,  C07D493/04

CPC classification number: A61K31/538 ,  A61K31/343 ,  A61K31/353 ,  A61K31/357 ,  A61K31/36 ,  A61K31/404 ,  A61K31/4045 ,  A61K31/472 ,  A61K45/06 ,  C07C235/22 ,  C07D209/08 ,  C07D209/42 ,  C07D217/16 ,  C07D265/36 ,  C07D307/85 ,  C07D311/66 ,  C07D317/46 ,  C07D319/20 ,  C07D405/12 ,  C07D413/06 ,  C07D413/12 ,  C07D493/04

Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.

公开(公告)号：US20220411433A1

公开(公告)日：2022-12-29

申请号：US17531039

申请日：2021-11-19

Applicant: Denali Therapeutics Inc.

Inventor： Robert A. Craig, II ,  Javier de Vicente Fidalgo ,  Anthony A. Estrada ,  Jianwen A. Feng ,  Brian M. Fox ,  Christopher R.H. Hale ,  Katrina W. Lexa ,  Maksim Osipov ,  Travis Remarchuk ,  Zachary K. Sweeney

IPC: C07D491/048 ,  C07C235/22 ,  C07D207/27 ,  C07D233/36 ,  C07D233/42 ,  C07D233/61 ,  C07D233/64 ,  C07D249/04 ,  C07D249/08 ,  C07D257/04 ,  C07D261/04 ,  C07D261/08 ,  C07D263/32 ,  C07D263/38 ,  C07D263/56 ,  C07D271/06 ,  C07D271/10 ,  C07D291/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.

公开(公告)号：US10995055B2

公开(公告)日：2021-05-04

申请号：US16685751

申请日：2019-11-15

Applicant: Insmed Incorporated

Inventor： Vladimir Malinin ,  Walter Perkins ,  Franziska Leifer ,  Donna Konicek ,  Zhili Li ,  Adam Plaunt

IPC: A61K9/14 ,  C07C69/734 ,  C07C69/712 ,  A61K47/60 ,  A61K47/54 ,  C07C69/736 ,  C07C69/753 ,  C07C235/22 ,  C07C235/20 ,  A61K31/165 ,  A61K31/216 ,  A61K31/225 ,  A61K47/06 ,  A61K9/00 ,  A61P9/12 ,  A61P11/00 ,  A61K9/10 ,  A61K9/51 ,  A61K47/14 ,  A61K47/24 ,  A61K47/28 ,  A61K47/34 ,  A61M15/00 ,  A61M16/14

Abstract: Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, branched C5-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom. Methods for treating pulmonary hypertension (e.g., pulmonary arterial hypertension) and portopulmonary hypertension are also provided.

公开(公告)号：US20150148414A1

公开(公告)日：2015-05-28

申请号：US14523538

申请日：2014-10-24

Applicant: Insmed Incorporated

Inventor： Vladimir Malinin ,  Walter Perkins ,  Franziska Leifer ,  Donna Konicek ,  Zhili Li ,  Adam Plaunt

IPC: C07C235/22 ,  C07C69/753 ,  C07C235/20 ,  C07C69/736

CPC classification number: A61K31/225 ,  A61K9/0075 ,  A61K9/0078 ,  A61K31/165 ,  A61K31/216 ,  A61K47/06 ,  A61K47/543 ,  A61K47/544 ,  A61K47/60 ,  C07C69/712 ,  C07C69/736 ,  C07C69/753 ,  C07C235/20 ,  C07C235/22 ,  C07C2601/18 ,  C07C2603/14

Abstract: Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, branched C5-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom. Methods for treating pulmonary hypertension (e.g., pulmonary arterial hypertension) and portopulmonary hypertension are also provided.

Abstract translation: 前列环素化合物和包含其的组合物在本文中提供。 具体地说，包括与直链C 5 -C 18烷基，支链C 5 -C 18烷基，直链C 2 -C 18烯基，支链C 3 -C 18烯基，芳基，芳基-C 1 -C 18烷基或氨基酸或肽（共价连接）共价连接的曲前列素的前列环素化合物 例如二肽，三肽，四肽）。 在一个实施方案中，连接是通过氨基甲酸酯，酰胺或酯键。 本文提供的前列环素化合物还可包括至少一个被至少一个氘原子取代的氢原子。 还提供了治疗肺动脉高压（例如肺动脉高压）和肺动脉高压的方法。

公开(公告)号：US5380733A

公开(公告)日：1995-01-10

申请号：US991239

申请日：1992-12-16

Applicant: George S. Cockerill ,  David A. Pulman ,  Robert J. Blade ,  Malcom H. Black

Inventor： George S. Cockerill ,  David A. Pulman ,  Robert J. Blade ,  Malcom H. Black

IPC: A01N37/18 ,  A01N43/08 ,  A01N43/40 ,  A01N43/46 ,  A01N43/54 ,  A01N43/56 ,  A01N43/78 ,  A01N43/80 ,  A01N43/82 ,  C07C235/22 ,  C07C235/24 ,  C07D211/06 ,  C07D213/30 ,  C07D213/75 ,  C07D213/81 ,  C07D231/38 ,  C07D231/40 ,  C07D239/26 ,  C07D239/42 ,  C07D261/14 ,  C07D263/48 ,  C07D277/20 ,  C07D277/44 ,  C07D277/46 ,  C07D285/12 ,  C07D285/135 ,  C07D295/18 ,  C07D295/32 ,  C07D307/33 ,  C07D417/12 ,  C07F9/24 ,  C07D405/10

CPC classification number: C07D213/75 ,  A01N37/18 ,  A01N43/08 ,  A01N43/40 ,  A01N43/46 ,  A01N43/54 ,  A01N43/56 ,  A01N43/78 ,  A01N43/80 ,  A01N43/82 ,  C07D231/38 ,  C07D239/42 ,  C07D261/14 ,  C07D277/46 ,  C07D285/135 ,  C07D295/32 ,  C07D307/33

Abstract: Compounds of the formula:Q(CH.sub.2).sub.a (O).sub.b Q.sub.1 CR.sub.2 .dbd.CR.sub.3 CR.sub.4 .dbd.CR.sub.5 CX.sub.1 NHR.sub.1wherein the terms Q, Q.sub.1, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, X.sub.1 and the integers a and b are defined in the specification, or salts thereof. Said compounds are useful as pesticides.

Abstract translation: 化合物Q（CH2）a（O）bQ1CR2 = CR3CR4 = CR5CX1NHR1其中术语Q，Q1，R1，R2，R3，R4，R5，X1和整体a和b在本说明书中定义，或盐 其中。 所述化合物可用作杀虫剂。

公开(公告)号：US4130413A

公开(公告)日：1978-12-19

申请号：US831480

申请日：1977-09-08

Applicant: Reinhard Handte ,  Gerhard Horlein ,  Helmut Kocher ,  Peter Langeluddeke

Inventor： Reinhard Handte ,  Gerhard Horlein ,  Helmut Kocher ,  Peter Langeluddeke

IPC: C07C69/712 ,  A01N31/08 ,  A01N37/36 ,  A01N39/02 ,  A01N43/08 ,  A01N43/20 ,  A01N43/40 ,  A01N43/52 ,  A01N43/72 ,  A01N43/74 ,  A01N43/76 ,  A01N43/78 ,  A01N47/12 ,  A01N47/16 ,  A01N47/18 ,  A01N47/20 ,  A01N47/22 ,  A01N47/24 ,  A01P13/00 ,  A61K31/41 ,  C07C41/00 ,  C07C41/26 ,  C07C43/29 ,  C07C43/295 ,  C07C51/00 ,  C07C51/367 ,  C07C59/125 ,  C07C59/58 ,  C07C59/68 ,  C07C67/00 ,  C07C67/343 ,  C07C69/67 ,  C07C69/68 ,  C07C201/00 ,  C07C205/38 ,  C07C219/06 ,  C07C231/00 ,  C07C231/12 ,  C07C235/20 ,  C07C235/22 ,  C07C235/24 ,  C07C241/00 ,  C07C243/28 ,  C07C253/00 ,  C07C255/16 ,  C07C255/37 ,  C07C313/00 ,  C07C323/12 ,  C07C325/00 ,  C07C327/22 ,  C07C327/42 ,  C07D213/64 ,  C07D213/643 ,  C07D235/26 ,  C07D263/54 ,  C07D263/58 ,  C07D277/66 ,  C07D277/68 ,  C07D303/48 ,  C07D307/12 ,  C07D307/42 ,  C07D413/12 ,  C07D277/62

CPC classification number: C07D213/643 ,  A01N39/02 ,  A01N43/08 ,  A01N43/20 ,  A01N43/40 ,  A01N43/52 ,  A01N43/74 ,  A01N43/76 ,  A01N43/78 ,  A01N47/12 ,  A01N47/16 ,  A01N47/18 ,  A01N47/20 ,  C07C243/00 ,  C07C59/68 ,  C07D235/26 ,  C07D263/58 ,  C07D277/68 ,  C07D307/12

Abstract: Compounds of the formula ##STR1## in which (R).sub.n is hydrogen, halogen, CF.sub.3, NO.sub.2, CN, alkyl, alkoxy or alkylthio,A is O, S, NH, or N-alkyl,R.sub.1 is hydrogen or alkyl andZ is a carboxylic acid, carboxylic ester, thiol ester, carbonamide, carbohydrazide, thioamide, nitrile, hydroxymethyl, acyloxymethyl, carbamoylmethyl, or sulfonyloxymethyl group,Are valuable herbicides for the selective control of weed grasses. The novel compounds are prepared by known methods, for example by reacting halo-benzthiazoles, -benzoxazoles or -benzimidazoles with unilaterally etherified hydroquinones.

Abstract translation: 式（I）化合物其中（R）n为氢，卤素，CF 3，NO 2，CN，烷基，烷氧基或烷硫基，A为O，S，NH或N-烷基，R 1为氢或烷基， Z是羧酸，羧酸酯，硫羟酸酯，碳酰胺，碳酰肼，硫代酰胺，腈，羟甲基，酰氧基甲基，氨基甲酰基甲基或磺酰氧基甲基。用于选择性控制草莓的有效除草剂。 新化合物通过已知方法制备，例如通过卤代 - 苯并噻唑，苯并恶唑或 - 苯并咪唑与单侧醚化的氢醌反应。

公开(公告)号：US11236100B2

公开(公告)日：2022-02-01

申请号：US16637718

申请日：2018-08-08

Applicant: Denali Therapeutics Inc.

Inventor： Robert A. Craig, II ,  Javier de Vicente Fidalgo ,  Anthony A. Estrada ,  Jianwen A. Feng ,  Brian M. Fox ,  Christopher R. H. Hale ,  Katrina W. Lexa ,  Maksim Osipov ,  Travis Remarchuk ,  Zachary K. Sweeney

IPC: C07D491/048 ,  C07C235/22 ,  C07C233/05 ,  C07C217/52 ,  C07C211/38 ,  C07D207/27 ,  C07D233/36 ,  C07D233/42 ,  C07D233/61 ,  C07D233/64 ,  C07D249/04 ,  C07D249/08 ,  C07D257/04 ,  C07D261/04 ,  C07D261/08 ,  C07D263/32 ,  C07D263/38 ,  C07D263/56 ,  C07D271/06 ,  C07D271/10 ,  C07D291/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.

公开(公告)号：US11220477B2

公开(公告)日：2022-01-11

申请号：US16418858

申请日：2019-05-21

Applicant: The Regents of the University of California

Inventor： Peter Walter ,  Carmela Sidrauski ,  Diego Acosta Alvear ,  Michelle R. Arkin ,  Christopher G. Wilson ,  Kean Hooi Ang ,  Brian R. Hearn ,  Punitha Vedantham ,  Adam R. Renslo ,  Mervyn Maze ,  Susana Vacas

IPC: C07C235/14 ,  C07F7/08 ,  A61K31/4192 ,  C07D403/12 ,  C07D495/04 ,  C07C255/54 ,  C07C257/14 ,  C07C271/24 ,  C07C271/52 ,  C07C211/29 ,  C07C317/22 ,  C07C317/44 ,  C07C323/60 ,  C07C235/20 ,  C07C235/22 ,  C07C235/24 ,  A61K31/165

Abstract: Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2α phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.

公开(公告)号：US20210147435A1

公开(公告)日：2021-05-20

申请号：US16637718

申请日：2018-08-08

Applicant: Denali Therapeutics Inc.

Inventor： Robert A. Craig, II ,  Javier de Vicente Fidalgo ,  Anthony A. Estrada ,  Jianwen A. Feng ,  Brian M. Fox ,  Christopher R.H. Hale ,  Katrina W. Lexa ,  Maksim Osipov ,  Travis Remarchuk ,  Zachary K. Sweeney

IPC: C07D491/048 ,  C07D413/04 ,  C07D271/10 ,  C07D249/04 ,  C07D261/04 ,  C07D261/08 ,  C07D263/32 ,  C07C235/22 ,  C07D249/08 ,  C07D233/61 ,  C07D413/12 ,  C07D487/04 ,  C07D471/04 ,  C07D413/06 ,  C07D403/12 ,  C07D401/12 ,  C07D271/06 ,  C07D263/38 ,  C07D207/27 ,  C07D233/42 ,  C07D233/36 ,  C07D403/04 ,  C07D263/56 ,  C07D233/64 ,  C07D257/04 ,  C07D417/04 ,  C07D291/04

Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.

公开(公告)号：US10010518B2

公开(公告)日：2018-07-03

申请号：US15154631

申请日：2016-05-13

Applicant: Insmed Incorporated

Inventor： Vladimir Malinin ,  Walter Perkins ,  Franziska Leifer ,  Donna Konicek ,  Zhili Li ,  Adam Plaunt

IPC: A61K31/225 ,  C07C69/736 ,  C07C69/753 ,  C07C235/22 ,  C07C235/20 ,  A61K31/165 ,  A61K31/216 ,  A61K47/06 ,  C07C69/712 ,  A61K9/00 ,  A61K47/60 ,  A61K47/54

CPC classification number: C07C69/734 ,  A61K9/0019 ,  A61K9/0043 ,  A61K9/0053 ,  A61K9/0073 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/10 ,  A61K9/14 ,  A61K9/51 ,  A61K31/165 ,  A61K31/216 ,  A61K31/225 ,  A61K47/06 ,  A61K47/14 ,  A61K47/24 ,  A61K47/28 ,  A61K47/34 ,  A61K47/543 ,  A61K47/544 ,  A61K47/60 ,  A61M15/0085 ,  A61M15/009 ,  A61M16/14 ,  A61M2202/064 ,  A61P9/12 ,  A61P11/00 ,  C07C69/712 ,  C07C69/736 ,  C07C69/753 ,  C07C235/20 ,  C07C235/22 ,  C07C2601/18 ,  C07C2603/14

Abstract: Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, branched C5-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom. Methods for treating pulmonary hypertension (e.g., pulmonary arterial hypertension) and portopulmonary hypertension are also provided.